ClinicalTrials.gg
RecruitingNCT07226466Updated Nov 16, 2026

Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer

An observational study in Brain Tumor Adult, Brain Metastases From Solid Tumors and Brain Tumor, Primary, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of California, San Francisco · Observational

How we know

Updated Nov 16, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Brain Neoplasms by University of California, San Francisco — 4 open to participants now, 4 under way, none of them phase 3. Brain Neoplasms · University of California, San Francisco.

Started
2026
with 1 other
Observational
3 of 14
2 open now
Registered
13th of 14
by date

Among the 14 studies in Brain Neoplasms by University of California, San Francisco, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 13th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

4 of the 14 studies in Brain Neoplasms by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Brain Neoplasms by University of California, San Francisco, or all of them as a file.
02

Study summary

This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological mechanisms remain unclear.

Read the detailed description

PRIMARY OBJECTIVES:

  1. Assess plasma biomarkers for Aβ, GFAP, phospho Tau, and NfL pre- and post-radiotherapy.
  2. Determine APOE genotype.
  3. Evaluate neuropsychiatric testing aligned with standard of care brain MRIs and serum markers.
  4. Measure brain morphometrics pre- and post-radiotherapy with standard of care brain MRIs.

SECONDARY OBJECTIVES:

1. Measure patient-reported quality of life changes pre- and post-radiotherapy using a standard University of California, San Francisco (UCSF) -approved questionnaire.

OUTLINE:

This is a single-arm, non-randomized, open-label pilot study. Participants will be study duration spans 12 months post-brain radiotherapy.

03

Conditions studied

  • Brain Tumor Adult
  • Brain Metastases From Solid Tumors
  • Brain Tumor, Primary
  • Brain Tumor

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult participants with brain cancers receiving care at University of California, San Francisco (UCSF)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. >= 18 years old
  2. Diagnosis of a primary brain tumor OR #3. Not both #2 and #3.
  3. Diagnosis of primary solid tumor and secondary involvement of the brain
  4. If the patient has : fewer than 5 brain metastases (post-operative and definitive allowed), none > 1 cm in max diameter.
  5. Candidate for standard of care / usual care (SOC) focused brain radiotherapy.
  6. No prior brain radiotherapy, including whole brain radiotherapy.
  7. (ECOG) functional score 0 or 1.
  8. Estimated post-treatment of > 2 years.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of neurodegenerative disease (Alzheimer's disease, Parkinson's disease).
  2. Diagnosis of memory disorder pre-treatment.
  3. or disease involving either hippocampus.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Adults with Brain Tumor Receiving Radiotherapy

    The study entails longitudinal assessment of plasma biomarkers (Aβ, GFAP, phospho Tau, NfL), determination of APOE genotype, neuropsychiatric testing Brain Health Assessment test (BHA), a clinically validated neurocognitive battery compiling metrics on memory and language), and brain morphometric measurements synchronized with standard of care brain MRIs.

    Procedure: Blood sample · Procedure: Brain magnetic resonance imaging (MRI) · Procedure: Brain Health Assessment · Radiation: Quality of Life (QoL) Questionnaire

Interventions

  • ProcedureBlood sample

    Blood sample will be collected

  • ProcedureBrain magnetic resonance imaging (MRI)

    Brain MRI will be performed during the course of data collection

  • ProcedureBrain Health Assessment

    Brain Health Assessment will be performed during the course of data collection

  • RadiationQuality of Life (QoL) Questionnaire

    QoL questionnaire will be given to participants during the course of data collection

06

What researchers measure

Primary outcomes

  1. Mean change in serum Amyloid-beta peptide (Aβ)

    Mean change in biomarker for Aβ over time will be reported

    Time frame: Up to 6 months

  2. Mean change in serum Amyloid-beta peptide (Aβ) by APOE genotype

    Mean change in biomarker for Aβ by APOE genotype over time will be reported

    Time frame: Up to 6 months

  3. Mean change of score on the European Organization for Research and Treatment of Cancer quality of life questionnaire - Brain Module (EORTC-QLQ-BN20)

    The EORTC QLQ-BN20 consists of 20 questions; seven single item symptom scales (headaches, seizures, drowsiness, hair loss, itchy skin, leg weakness and bladder control), along with four multi-item scales (future uncertainty, visual disorder, motor dysfunction and communication deficit). Raw scores for the QLQ-BN20 items are computed by calculating the mean of the items in each subscale, or the item for each individual and linearly transform the scores to a 0-100 scale. A higher score represents worse QOL for all QLQ-BN20 scales and single items.

    Time frame: Up to 18 months from date of first radiation dose

  4. Mean change in serum Glial Fibrillary Acidic Protein (GFAP)

    Mean change in biomarker for GFAP over time will be reported

    Time frame: Up to 6 months

  5. Mean change in serum Glial Fibrillary Acidic Protein (GFAP) by APOE genotype

    Mean change in biomarker for GFAP by APOE genotype over time will be reported

    Time frame: Up to 6 months

  6. Mean change in serum Phosphorylated TAU (p-TAU)

    Mean change in biomarker for p-TAU over time will be reported

    Time frame: Up to 6 months

  7. Mean change in serum Phosphorylated TAU (p-TAU) by APOE genotype

    Mean change in biomarker for p-TAU by APOE genotype over time will be reported

    Time frame: Up to 6 months

  8. Mean change in serum Neurofilament Light Chain (NfL)

    Mean change in biomarker for NfL over time will be reported

    Time frame: Up to 6 months

  9. Mean change in serum Neurofilament Light Chain (NfL) by APOE genotype

    Mean change in biomarker for NfL by APOE genotype over time will be reported

    Time frame: Up to 6 months

  10. Mean change in Brain Health Assessment by APOE genotype

    Mean change in of Brain Health Assessment by APOE genotype over time will be reported

    Time frame: Up to 6 months

  11. Mean change in Hippocampal Volume

    Mean change in Hippocampal Volume as measured by MRI over time will be reported

    Time frame: Up to 6 months

  12. Mean change in Hippocampal Volume by APOE genotype

    Mean change in Hippocampal Volume as measured by MRI by APOE genotype over time will be reported

    Time frame: Up to 6 months

Secondary outcomes

  1. Change in scores on the European Organization for Research and Treatment of Cancer quality of life questionnaire 30 (EORTC-QLQ-C30) over time

    The functional domains measure the quality of life in Physical functioning, Role functioning, Emotional functioning, Cognitive functioning, Social functioning. Scores consists of responses to items with responses ranging from 1="Not at all" to 4="Very Much". The raw score is calculated by estimating the mean of the items that make up each domains with a resulting total range of 1 - 4. These scores are then transformed to standardized scale score, so that scores range from 0 to 100. A high score for the functional domains represents a high level of functioning.

    Time frame: Up to 18 months from date of first radiation dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Feb 2029, 27 months after the start.

Of 182 non-industry observational studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 269. This study's planned 27 months is below that.

Counting every sponsor, half of 200 studies reached it within 82 months; a quarter within 41 and three quarters within 269.

Start moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, last on Nov 16, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2028 → Feb 2029, on Oct 15, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Dec 2028 → Aug 2029, last on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2025
First posted
Nov 10, 2025
StartActual
Nov 2, 2026was Sep 2026
Primary completionEst.
Feb 28, 2029was Dec 2028
CompletionEst.
Aug 31, 2029was Dec 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
University of California, San Francisco is now Recruiting
Nov 16, 2026
Start date
Sep 1, 2026→Nov 2, 2026 (actual)
moved 2 times, Oct 15, 2026 – Nov 16, 2026
Primary completion
Dec 31, 2028→Feb 28, 2029
Oct 15, 2026
Study completion
Dec 31, 2028→Aug 31, 2029
moved 2 times, Oct 15, 2026 – Nov 16, 2026
Primary outcomes
11 time frame changed
What changed in the outcomes
  • Time frameMean change in serum Amyloid-beta peptide (Aβ)Up to 12 months → Up to 6 months
  • Time frameMean change in serum Amyloid-beta peptide (Aβ) by APOE genotypeUp to 12 months → Up to 6 months
  • Time frameMean change in serum Glial Fibrillary Acidic Protein (GFAP)Up to 12 months → Up to 6 months
  • Time frameMean change in serum Glial Fibrillary Acidic Protein (GFAP) by APOE genotypeUp to 12 months → Up to 6 months
  • Time frameMean change in serum Phosphorylated TAU (p-TAU)Up to 12 months → Up to 6 months
  • Time frameMean change in serum Phosphorylated TAU (p-TAU) by APOE genotypeUp to 12 months → Up to 6 months
  • Time frameMean change in serum Neurofilament Light Chain (NfL)Up to 12 months → Up to 6 months
  • Time frameMean change in serum Neurofilament Light Chain (NfL) by APOE genotypeUp to 12 months → Up to 6 months
  • Time frameMean change in Brain Health Assessment by APOE genotypeUp to 12 months → Up to 6 months
  • Time frameMean change in Hippocampal VolumeUp to 12 months → Up to 6 months
  • Time frameMean change in Hippocampal Volume by APOE genotypeUp to 12 months → Up to 6 months
Oct 29, 2026
Show all 3 updates
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    University of California, San Francisco is now Recruiting
    Start date Dec 15, 2026→Nov 2, 2026 (now actual)
    Study completion Feb 28, 2029→Aug 31, 2029
    + 1 other change: verification date
  2. Oct 29, 2026
    Primary outcomes 11 time frame changed
    What changed in the outcomes
    • Time frameMean change in serum Amyloid-beta peptide (Aβ)Up to 12 months → Up to 6 months
    • Time frameMean change in serum Amyloid-beta peptide (Aβ) by APOE genotypeUp to 12 months → Up to 6 months
    • Time frameMean change in serum Glial Fibrillary Acidic Protein (GFAP)Up to 12 months → Up to 6 months
    • Time frameMean change in serum Glial Fibrillary Acidic Protein (GFAP) by APOE genotypeUp to 12 months → Up to 6 months
    • Time frameMean change in serum Phosphorylated TAU (p-TAU)Up to 12 months → Up to 6 months
    • Time frameMean change in serum Phosphorylated TAU (p-TAU) by APOE genotypeUp to 12 months → Up to 6 months
    • Time frameMean change in serum Neurofilament Light Chain (NfL)Up to 12 months → Up to 6 months
    • Time frameMean change in serum Neurofilament Light Chain (NfL) by APOE genotypeUp to 12 months → Up to 6 months
    • Time frameMean change in Brain Health Assessment by APOE genotypeUp to 12 months → Up to 6 months
    • Time frameMean change in Hippocampal VolumeUp to 12 months → Up to 6 months
    • Time frameMean change in Hippocampal Volume by APOE genotypeUp to 12 months → Up to 6 months
  3. Oct 15, 2026
    Start date Sep 1, 2026→Dec 15, 2026
    Primary completion Dec 31, 2028→Feb 28, 2029
    Study completion Dec 31, 2028→Feb 28, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07226466
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Nov 2, 2026
Primary completion
Feb 28, 2029 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Jean Nakamura, MD
Contact
Jean.Nakamura@ucsf.edu
(415) 514-4997
Jean Nakamura, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion